Introduction
Excessive alcohol consumption is the primary cause of liverrelated mortality in Western countries. 1 Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease (ALD) and there is an urgent need to develop novel targeted therapies for severe AH. 2 Multiple molecular and cellular mechanisms contribute to the development of ALD. Prolonged alcohol abuse leads to an imbalance between intracellular antioxidant defense systems and the production of free radical species, promoting lipid peroxidation. 3 Injury to hepatocytes can result in the release of danger-associated molecular patterns (DAMPs) which can activate pathways of sterile inflammation. 3 Chronic alcohol consumption also impairs the barrier function of the intestine and promotes bacterial dysbiosis, resulting in increased translocation of pathogen-associated molecular patterns (PAMPs) from the gastrointestinal lumen to the liver through the portal vein. 1 MIF is produced by both hepatocytes and Kupffer cells. 6 MIF signals via the interaction with the CD74 receptor, 7 as well as its coreceptors CXCR2, CXCR4 and CXCR7. 8 These receptors are expressed both on resident hepatic macrophages 9 and peripheral monocytes; 10 therefore, MIF release results in both activation of resident macrophages and recruitment of innate immune cells from the periphery. MIF concentration is increased in the circulation of patients with ALD, 11 as well as in mice in response to chronic ethanol feeding. 5 Since mice deficient in MIF are protected from ethanol-induced liver injury, 5 it is important to determine the cellular source of MIF in response to ethanol exposure. Making use of cell culture and mouse models, as well as clinical samples from patients with AH, we provide evidence that hepatocytederived MIF is important for the progression of ethanol-induced liver injury. Taken together, these data indicate that MIF released from injured hepatocytes likely serves as a DAMP in the progression of ALD, resulting in the recruitment of innate immune cells to the liver and activation of inflammatory pathways. Our results suggest that interfering with the release and/or signaling of MIF may be a viable therapeutic option in the prevention and/or treatment of ALD.
Materials and methods

Cell lines and cell culture
HuH7 is a well-differentiated hepatocyte-derived carcinoma cell line, obtained from Japan Health Science Research Resources Bank (HSRRB, JCRB0403). THP-1 is an acute monocytic leukemia derived cell line (ATCC Ò TIB-202 TM ). HuH7 and THP-1 cells were cultured as previously described. 12 Mycoplasma contamination has been excluded by testing the cultures periodically using fluorescent staining (Hoechst 33258). Cells were treated with or without 50 mM ethanol or 200 ng/ml lipopolysaccharides ([LPS] from E. coli serotype O127:B8), as detailed in the figure legends.
Generation of bone marrow chimeric mice and ethanol feeding
Female C57BL/6 (wild-type [WT]) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mif À/À mice on a C57BL/6 background were obtained from Dr. R. Bucala (Yale University, New Haven, CT, USA) 13 and a breeding colony was established at Cleveland Clinic. All procedures using animals were approved by the Cleveland Clinic Institutional Animal Care and Use Committee. Bone marrow chimeras between WT and Mif À/À mice were generated as previously described 14 (see schematic of protocol in Fig. S1 ). Four weeks post-transplant, chimeras were treated with clodronate-containing liposomes (Encapsula NanoSciences, Nashville, TN SKU # 8909) to deplete resident macrophages in the liver. 15 Seven days post-clodronate, chimeras were placed on the Lieber-DeCarli ethanol diet or pairfed control diets for 25 days. 16 See Supplementary data for additional details of the feeding protocol. Mouse body weight and food intakes are shown in Table S2 .
Plasma ALT and AST and liver triglycerides
Plasma alanine aminotransferase (ALT) and plasma aspartate aminotransferase (AST) assay kits were purchased from Sekisui Diagnostics (Framingham, MA 
Cytokine ELISAs
Cell culture media/Human serum ELISA was performed in cell culture media and in patient serum following the manufacturer's instruction (Human MIF Quantikine ELISA Kit, R&D System; Human TNF-a Instant ELISA, eBioscience). 
Statistics
Values are reported as means ± standard error of the mean (SEM). Data were analyzed by analysis of variance (ANOVA) using general linear models procedure (SAS, Cary, NC). If data were not normally distributed, data were log transformed. Multiple comparisons were analyzed using least square means. For human data, correlations between variables were evaluated using Spearman's rho or Pearson's r, when appropriate. For further details regarding the materials used, please refer to the Supplementary data and CTAT table.
Results
Hepatocytes (HuH7), but not monocyte-derived cells (THP-1), release MIF in response to ethanol challenge
To understand the cellular sources of MIF in the context of ethanol exposure, HuH7 hepatocytes and differentiated THP-1 monocytes were treated with or without ethanol or LPS. Challenge of HuH7 with ethanol for 4-24 h increased MIF mRNA, while LPS only increased MIF mRNA after 24 h (Fig. 1A) . Ethanol induced the release of MIF (but not TNF-a) from HuH7 starting after 8 h (Fig. 1B, C) . In contrast, challenge of THP-1 cells with ethanol did not increase MIF mRNA (Fig. 1D ) or release of MIF (Fig. 1E ). However, LPS modestly increased MIF mRNA at 24 h ( Fig. 1D ) and stimulated release of MIF and TNFa as early as 4 h (Fig. 1E, F ). These data suggested that hepatocytes might be an important source of MIF in the liver in response to ethanol exposure. Fig. 2A-C) . Hepatic steatosis and inflammatory foci were also observed in H&E stained sections of liver from ethanol-fed WT ? WT and Mif À/À ? WT mice (Fig. 2D) . Chronic ethanol feeding to WT ? WT and Mif À/À ? WT mice also increased TUNEL positive nuclei in the liver (Fig. 2E) . In contrast, WT ? Mif À/À mice were resistant to chronic ethanol-induced increases in ALT/AST, hepatic steatosis, inflammatory infiltrates and apoptosis ( Fig. 2A-E (Fig. 3B, C) . Ly6C + cells also clustered into inflammatory foci, as observed on H&E stained liver sections (Fig. 2D) . Taken together, these data from chimeric mice suggest that bone marrow-derived cells do not contribute to MIF release after ethanol feeding in mice. Instead, non-myeloid cells represent the critical cell type generating MIF in response to chronic ethanol feeding. Importantly, the absence of MIF in non-myeloid cells protected mice from chronic ethanol-induced liver injury to a similar extent as in global MIF-deficient mice. 5 
MIF expression in non-myeloid cells contribute to ethanol-induced liver injury in chimeric mice
MIF expression in the liver of patients with alcoholic hepatitis
We next investigated the expression and localization of MIF in liver biopsies from patients with AH, autoimmune hepatitis (disease control) and non-diseased controls. Increased MIF staining was detected in liver biopsies from patients with AH, as well as autoimmune hepatitis, compared with controls (Fig. 4A) . Expression of MIF mRNA was increased 1.4-fold in patients with AH compared to healthy controls (Fig. 4B) . However, the cellular localization differed between AH and autoimmune hepatitis. MIF was predominantly localized to hepatocytes and ductular cells in AH patients, while MIF was primarily localized in nonparenchymal cells in autoimmune hepatitis. Hepatocytes and non-parenchymal cells were identified according to their cellular and nuclear morphology. Although the majority of MIF staining was localized in the cytosol of hepatocytes, nuclear staining was also detected in a few cells in sections from patients with AH.
Positive correlation between MIF in suprahepatic serum and biochemical markers of liver disease in patients with alcoholic hepatitis
If hepatocytes are an important source of MIF in response to ethanol, then the concentration of MIF in suprahepatic serum should be correlated with the extent of liver disease in patients with AH. To test this hypothesis, MIF was quantified in peripheral and suprahepatic serum. The concentration of circulating MIF correlated with parameters indicative of disease severity. Peripheral serum levels positively correlated with suprahepatic serum levels. A positive correlation was found between MIF concentration in the suprahepatic, but not peripheral, serum including bilirubin, AST, circulating triglycerides and GGT (Table 2 and Fig. 4C-G) . Increased MIF in the suprahepatic serum (Fig. 4H ), but not peripheral serum (Fig. 4I) , was also associated with an increased risk of mortality.
Discussion
Chronic, heavy alcohol consumption results in injury to hepatocytes, at least in part due to the oxidative stress resulting from ethanol metabolism, as well as the development of inflammation in the liver. 19 However, the complex mechanisms linking hepatocyte injury to inflammation are not completely understood.
Release of DAMPs from injured hepatocytes activates the resident Kupffer cells in the liver, 20 leading to production of chemokines and further recruitment of immune cells to the liver. 19 Recent data also suggests that hepatocytes release chemokines in response to injury, thus adding to the recruitment of more immune cells. 21 MIF, a potent chemokine, is released by both immune cells 22 and hepatocytes 11, 23 in other disease models. Since MIF is a critical mediator of ethanol-induced liver injury, here we sought to identify the predominant cellular source of MIF in response to ethanol exposure. Challenge of HuH7 hepatocytes, but not THP-1 macrophages, with ethanol resulted in the accumulation of MIF in the cell culture media. Importantly, chimeric mice deficient in MIF in non-myeloid cells were protected from chronic ethanol-induced liver injury. Finally, patients with AH had increased expression of MIF in hepatocytes and accumulation in the circulation. The concentration of MIF in the suprahepatic serum correlated with multiple clinically-relevant parameters indicative of disease severity, as well as the risk of death from AH. Taken together, these data suggest that hepatocytes are an important source of MIF in response to chronic ethanol feeding in mice and patients with AH and that the release of MIF from hepatocytes likely provides an important link between hepatocyte injury from ethanol and an exacerbation of inflammation in the liver.
Despite its name, MIF has significant chemotactic activity and is a potent enhancer of macrophage activity, increasing phagocytosis, as well as expression of inflammatory cytokines and inducible nitric oxide synthase. 24 MIF upregulates the expression of major histocompatibility complex II molecules, co-stimulatory and adhesion molecules, as well as cytokines, in a wide variety of cell types including Kupffer cells, peritoneal macrophages and dendritic cells. 25 MIF also maintains macrophage viability by suppressing activation-induced macrophage apoptosis by inhibiting p53. 26 Thus, the ability of MIF to act as a chemokine, as well as to prevent activation-induced apoptosis, increases expression of inflammatory mediators and contributes to MIF's profound pro-inflammatory effects. MIF plays an important role in the liver in response to acute and chronic stress, 27 contributing to T cell mediated injury in murine ethanol-induced liver damage. 5 In contrast, MIF can also have protective effects at specific phases of liver disease. For example, MIF is required for the recruitment of scar-associated macrophages to the liver; these macrophages are critical for the resolution of fibrosis after an injury. 28 This recruitment likely contributes to the protective function of MIF and its receptor CD74 in response to fibrotic insults. 29 Taken together, these studies suggest a complex interaction between MIF in the progression of liver disease.
Given this complex role, here we first investigated the direct effects of ethanol on HuH7 cells and differentiated THP-1 macrophages, as cellular models of the primary cell types expressing MIF in the liver. When HuH7 cells were challenged with ethanol, Although MIF has direct chemokine activity, it can also indirectly influence immune cell recruitment via modulation in the expression of other chemokines. For example, MIF upregulates MCP-1 expression in an autocrine mechanism in mouse liver or hepatocytes following acute CCl 4 exposure. 23 MCP-1 contributes to progression of ethanol-induced liver injury, particularly related to its ability to act both as a chemokine and steatokine. 30 Here we find that in WT ? Mif
, expression of mRNA for some chemokines, including MCP-1, CXCL1, CXCL2 and CXCL10 after ethanol feeding was lower than in Mif À/À ? WT (Fig. 3) . Interestingly, CXC chemokines, mainly derived from hepatocytes, are known to correlate with mortality in AH. 31 Taken together, these data indicate that MIF released from non-myeloid cells in response to ethanol-induced liver injury acted as a signal regulating the expression of a network of chemokines known to be important for the progression of ethanol-induced liver injury. Our cell culture and mouse studies suggest that MIF is an important danger signal released from hepatocytes in response to ethanol-induced injury. Here we also report that MIF expression, both at the level of mRNA and protein, was increased in livers of patients with AH. IHC revealed a predominant expression of MIF in hepatocytes in AH patients compared to both healthy liver controls and patients with autoimmune hepatitis. Kumagi et al. 11 reports that MIF concentrations in the circulation were increased in relation to disease severity in patients with ALD. If this increase in circulating MIF was derived from injured hepatocytes and/or other liver cell types, then MIF concentration in suprahepatic serum should be correlated with the extent of hepatocyte injury in patients with AH. This hypothesis is supported by our finding that suprahepatic, but not peripheral, MIF correlated with bilirubin, AST, GGT and circulating triglycerides, as well as with short-term mortality in AH patients. It will also be important in future experiments to determine if there are posttranslational modifications to MIF in patients with AH, such as the redox-dependent conformational isoforms reported in other inflammatory diseases. 35 It is interesting to note that MIF has protective effects on hepatocytes in the face of high fat diet-induced injury. 34 Clearly, our data suggest that this potential hepatoprotective effect of MIF is not sufficient to protect hepatocytes in the context of ethanol exposure. Instead, it is likely that the pro-inflammatory, chemotactic properties of MIF are predominant in AH. These differential effects of MIF are likely related to its interactions with multiple receptors. The cytokine activity of MIF, as well as its protective effects on hepatocytes, is largely due to binding to the CD74/ CD44 receptor complex. 9, 25 In contrast, its chemokine activity is exerted through the formation of different homo-and heterodimers of the CXCR2, CXCR4 and CXCR7 receptors, possibly also in coordination with CD74. 10, 36, 37 These differences in MIF function will be important to keep in mind during the development of potential therapeutic interventions to inhibit MIF action.
In conclusion, our present findings reveal that MIF was released from non-myeloid cells during the progression of ethanol-induced liver injury. Our data are consistent with a predominant role for hepatocyte injury in driving the release of MIF. It is interesting to note that MIF release from injured hepatocytes functions in a similar manner to classic DAMPs, signaling sterile inflammation and the recruitment of inflammatory cells to the site of injury. Strategies to specifically dampen the chemotactic, rather than the potential hepatoprotective effects of MIF are likely to be a relevant therapeutic approach in treating AH.
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